A patient with lung cancer was administrated osimertinib. She developed symptomatic heart failure due to Takotsubo-cardiomyopathy (TC). As her condition improved after discontinuing osimertinib, TC was thought to be caused by osimertinib. Re-occurrence of TC was seen after re-administraing half dose of osimernitib.